| Code | CSB-RA011719MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to garetosmab, targeting inhibin beta A (INHBA), also known as activin A. INHBA encodes a subunit of activin A, a member of the TGF-β superfamily that plays critical roles in cellular proliferation, differentiation, and inflammatory responses. Activin A is implicated in various pathological conditions including fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive heterotopic ossification, as well as cancer progression, fibrotic diseases, and inflammatory disorders. Elevated activin A levels have been associated with aberrant bone formation and tissue remodeling processes.
Garetosmab is a therapeutic antibody developed to neutralize activin A signaling, primarily investigated for treating FOP by preventing heterotopic bone formation. This biosimilar antibody provides researchers with a valuable tool for investigating activin A-mediated pathways, studying mechanisms of ectopic bone formation, exploring TGF-β superfamily signaling networks, and evaluating potential therapeutic interventions for FOP and related musculoskeletal disorders. It enables preclinical studies examining the role of activin A in tissue repair, inflammation, and pathological ossification.
There are currently no reviews for this product.